Belly fat, especially the deep “visceral” fat around your organs, is linked to higher risks of heart disease, diabetes, and inflammation. Two peptides studied for attacking this stubborn fat are AOD-9604 (a fragment of growth hormone) and Tesamorelin (a growth hormone-releasing hormone analog). Tesamorelin is FDA-approved for reducing visceral fat in certain patients, while AOD-9604 focuses on fat breakdown. Together, they are discussed as a strong combo for people who want to aggressively target abdominal fat. No large primary trials test the exact pair, but their individual studies show complementary ways of working. This article uses peer-reviewed clinical data.
What Are These Compounds?
- AOD-9604 is the last 16 amino acids of human growth hormone. It was designed to keep the fat-burning part while avoiding full GH side effects like raised IGF-1 or blood sugar changes.
- Tesamorelin is a lab-made version of growth hormone-releasing hormone (GHRH). It tells the pituitary gland to release natural pulses of growth hormone.
The stack idea: Tesamorelin raises natural GH to reduce deep belly fat, while AOD-9604 adds direct fat mobilization—together aiming for faster, more focused abdominal fat loss.
Tesamorelin: Proven Visceral Fat Reducer
Tesamorelin has the strongest evidence for targeting visceral adipose tissue (VAT). In two large Phase 3 trials with over 800 HIV patients who had excess belly fat, 2 mg daily for 26 weeks reduced visceral fat by about 15% (around 15–18% in pooled data) while subcutaneous (under-skin) fat and overall weight stayed mostly the same.
- 69% of people on tesamorelin achieved at least 8% VAT reduction (the FDA’s defined meaningful change) vs. 33% on placebo.
- It also improved triglycerides and cholesterol ratios.
- Benefits lasted up to a year in extension studies, with waist size dropping and some liver fat improvements.
It works by gently increasing natural GH pulses, which promote lipolysis (fat breakdown) especially in the dangerous visceral depot.
AOD-9604: Fat-Burning Support
AOD-9604 stimulates lipolysis in fat cells. In obese mice, it reduced body weight and fat without affecting muscle.
Human trials (over 900 people): It was safe with few side effects and no IGF-1 or glucose changes. Early smaller studies showed modest extra weight loss (about 2–3 kg more than placebo over 12 weeks). Larger later trials with strict diet/exercise had mixed or weaker results for overall weight, but some reports noted better effects on abdominal fat. It does not suppress appetite but may help the body burn stored fat more efficiently.
Why Stack Them? Potential Synergy for Aggressive Abdominal Fat Loss
- Tesamorelin reliably reduces deep visceral fat through natural GH pathways and has FDA-level evidence.
- AOD-9604 adds direct fat-mobilizing action that may enhance breakdown of stubborn abdominal stores.
Clinics often combine them hoping for better body composition results—more visceral fat loss with preserved muscle—than either alone. The mechanisms overlap nicely: GH stimulation (Tesamorelin) + targeted lipolysis (AOD-9604). Direct combination trials are lacking, but real-world use and logic support targeting belly fat from two angles.
Important Caveats from the Science
Tesamorelin has the strongest human data and is FDA-approved for HIV-related visceral fat. AOD-9604 is safe in trials but showed only modest or inconsistent weight/fat loss in larger studies. Neither is approved for general weight loss or cosmetic fat reduction. Side effects: injection-site reactions, possible joint aches or water retention (Tesamorelin); very few for AOD-9604. Long-term safety of the unregulated stack is unknown, and product quality varies. These are research tools—not magic bullets. They work best with diet, exercise, and medical supervision. Always consult a doctor.
The Bottom Line
Primary studies show Tesamorelin consistently reduces dangerous visceral abdominal fat by 15%+ in rigorous Phase 3 trials, while AOD-9604 supports fat mobilization with a clean safety profile. Together they offer a focused approach for aggressively targeting belly fat through complementary GH and lipolysis pathways. Promising for body composition goals, but larger controlled human trials on the combination are still needed. Science continues developing better tools to help people reduce harmful abdominal fat and improve metabolic health.
This information is not medical advice. Results vary by individual, and these compounds should be used only under the supervision of a qualified healthcare provider with appropriate monitoring (including regular bloodwork). They are not substitutes for a healthy diet, exercise, sleep, or standard medical care. Always consult your doctor before starting any peptide or compounded regimen.
